Synthetic Hormones Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Steroid Hormones is the fastest growing sector, North America is the largest market

The Global Synthetic Hormones Market is projected to expand significantly, growing from USD 619.12 Million in 2025 to USD 1.24 billion by 2031, demonstrating a robust 12.31% Compound Annual Growth Rate. These synthetic hormones are laboratory-created chemical compounds designed to emulate the biological functions of natural hormones, finding crucial applications in contraceptives, hormone replacement therapies, and treatments for various endocrine imbalances. The primary factors fueling this market growth include the rising incidence of chronic hormonal disorders and an aging worldwide population that increasingly requires therapeutic interventions for conditions such as menopause, with hormone therapy usage among women aged 40 to 60 years reaching 13% in 2025, according to The Menopause Society. Furthermore, ongoing advancements in reproductive medicine aimed at addressing fertility challenges are continuously stimulating industry development.

However, the market's growth is considerably constrained by ongoing safety apprehensions regarding the prolonged use of synthetic hormone products. The potential for serious adverse effects, including cardiovascular complications and various malignancies, necessitates stringent regulatory oversight and contributes to patient reluctance, thereby impeding the widespread adoption of these therapies.

Market Drivers

A primary catalyst for the Global Synthetic Hormones Market is the escalating prevalence of chronic endocrine and hormonal disorders, notably obesity and diabetes. Synthetic analogs, such as GLP-1 receptor agonists, are increasingly employed to mimic natural hormones, offering effective management for metabolic imbalances by regulating appetite and insulin levels. This extensive therapeutic adoption is reflected in the substantial revenue growth reported by leading pharmaceutical companies specializing in these treatments; for instance, Novo Nordisk's 'Annual Report 2024' indicated a 57% surge in sales within its Obesity Care segment, reaching DKK 65.1 billion by February 2025, which underscores the vital role of synthetic hormone interventions in addressing contemporary global health crises.

Concurrently, rising infertility rates are aggressively propelling the adoption of Assisted Reproductive Technologies (ART), which heavily depend on synthetic gonadotropins for ovarian stimulation and cycle management. Factors such as deferred childbearing and environmental stressors have intensified the global burden of reproductive health issues, necessitating medical intervention. Illustrating this widespread challenge, the World Health Organization reported in November 2025 that approximately one in six people of reproductive age globally experience infertility during their lifetime. This high prevalence sustains robust market demand for hormonal treatments; according to Merck KGaA's 'Annual Report 2024' from March 2025, the company's Fertility franchise generated sales of €1.5 billion, highlighting the significant economic contribution of hormone-based fertility solutions.

Market Challenges

Persistent safety concerns surrounding the long-term use of synthetic hormone products present a significant obstacle to the expansion of the Global Synthetic Hormones Market. The documented association of these therapies with severe adverse effects, particularly cardiovascular complications and malignancies, mandates rigorous regulatory oversight, which subsequently prolongs product approval processes and escalates compliance costs. This environment of heightened scrutiny cultivates considerable hesitation among both healthcare providers and patients, who frequently weigh the therapeutic advantages against the potential for life-threatening risks. Consequently, this apprehension curtails the eligible patient population as individuals increasingly seek non-hormonal treatment alternatives.

The impact of these safety fears is further amplified by the high prevalence of specific health conditions linked to hormonal interventions. For example, the American Cancer Society projected approximately 316,950 new cases of invasive breast cancer in women in the United States in 2025. The sheer scale of such health statistics reinforces public and clinical caution concerning treatments historically associated with increased cancer risks. As a result, safety-related reluctance effectively dampens demand and restricts the broader commercial adoption of synthetic hormone therapies.

Market Trends

Innovation in non-invasive oral peptide hormone formulations is transforming the market by introducing needle-free alternatives to traditional injectables, which were historically standard due to peptides' susceptibility to gastric degradation. New permeation-enhancing technologies now facilitate the effective oral delivery of synthetic hormones, such as semaglutide, significantly boosting patient compliance by eliminating the physical and psychological barriers associated with injections. This technological shift is driving substantial commercial adoption among patients managing type 2 diabetes who prioritize convenience over invasive administration methods. This rapid market uptake is evidenced by Novo Nordisk's 'Annual Report 2024' from February 2025, which reported a 24% increase in sales of the oral peptide formulation Rybelsus, reaching DKK 23.3 billion, thus confirming robust demand for effective non-invasive therapeutic options.

Simultaneously, the development of long-acting and sustained-release injectables is revolutionizing treatment regimens by dramatically reducing dosing frequency. Manufacturers are employing advanced prodrug engineering and carrier technologies to extend the biological half-life of synthetic hormones, converting burdensome daily protocols into more manageable weekly administrations. This trend is particularly significant in pediatric endocrinology, where minimizing injection frequency is crucial for enhancing therapy adherence and improving the quality of life for children with growth hormone deficiencies. Validating this trajectory, Ascendis Pharma's 'Fourth Quarter and Full Year 2024 Financial Results' from February 2025 showed full-year 2024 revenue for the once-weekly long-acting growth hormone Skytrofa totaling approximately €202 million, underscoring the strong clinical and commercial preference for sustained-release interventions.

Key Market Players

• Acerus Pharmaceuticals Corp.
• American Regent, Inc.
• Anhui Anke Biotechnology (Group) Co. Ltd.
• BioPartners, Inc
• Eli Lilly and Company
• Endo Pharmaceuticals, Inc.
• F. Hoffmann-La Roche Ltd.
• IBSA Institut Biochimique SA
• Lupin Pharmaceuticals, Inc.
• Pfizer, Inc

Report Scope

In this report, the Global Synthetic Hormones Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Synthetic Hormones Market, by Product:

• Amino Acid Derivatives
• Peptide Hormone
• Steroid Hormones

Synthetic Hormones Market, by Route of Administration:

• Intravenous
• Nasal
• Oral
• Suppository
• Topical

Synthetic Hormones Market, by Application:

• Growth Hormone Deficiency
• Male Hypogonadism
• Menopause
• Thyroid Hormone Deficiency

Synthetic Hormones Market, by End User:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Synthetic Hormones Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Synthetic Hormones Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.